DUBLIN--(BUSINESS WIRE)--The "Hereditary Angioedema - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Hereditary Angioedema (HAE), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hereditary Angioedema (HAE) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted HAE symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hereditary Angioedema (HAE) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Scope of the Report
- The report covers the descriptive overview of Hereditary Angioedema (HAE), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
- Comprehensive insight has been provided into the Hereditary Angioedema (HAE) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Hereditary Angioedema (HAE) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Hereditary Angioedema (HAE) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hereditary Angioedema (HAE) market
Report Highlights
- In the coming years, Hereditary Angioedema (HAE) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Hereditary Angioedema (HAE) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for HAE. Launch of emerging therapies will significantly impact the Hereditary Angioedema (HAE) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HAE.
- The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Key Topics Covered:
1. Key Insights
2. Hereditary Angioedema (HAE): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of HAE in 2017
2.2. Total Market Share (%) Distribution of HAE in 2030
3. Executive summary
4. Organizations
5. Epidemiology and Market Methodology
6. Hereditary Angioedema (HAE): Disease Overview
6.1. Introduction
6.2. Types of Hereditary Angioedema
6.3. Symptoms
6.4. Clinical Presentation
6.5. Risk Factors
6.6. Pathophysiologic and Immunologic Features of HAE
6.6.1. Mechanisms of Edema Formation
6.6.2. Genetics of HAE
6.7. Diagnosis of Hereditary Angioedema
6.7.1. Laboratory Findings
6.7.2. Prenatal and Postnatal Diagnosis
6.7.3. Delayed Diagnosis of HAE - A Persistent Problem with Serious Consequences
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total Diagnosed Prevalent Population of Hereditary Angioedema in 7MM
7.3. United States
7.4. Europe
7.5. Germany
7.6. France
7.7. Italy
7.8. Spain
7.9. UK
7.10. Japan
8. Treatment of Hereditary Angioedema
8.1. On-demand treatment
8.2. Prophylactic treatment
8.3. Home therapy and self-administration
8.4. WAO Guideline for the Management of Hereditary Angioedema
8.5. Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese Association for Complement Research
8.6. AAAAI Allergy and Asthma Medication Guide
8.7. The International Hereditary Angioedema Guideline
9. Unmet Needs
10. Marketed drugs
10.1. Takhzyro: Takeda
10.2. Firazyr: Shire/Takeda
10.3. Cinryze: Shire/Takeda
10.4. Kalbitor: Shire/Takeda
10.5. Haegarda: CSL Behring
10.6. Berinert: CSL Behring
10.7. Ruconest: Pharming Group
11. Emerging Therapies
11.1. Key Cross Competition
11.2. BCX7353: BioCryst Pharmaceuticals
11.3. IONIS-PKK-LRx: Ionis Pharmaceuticals
11.4. KVD900: KalVista Pharmaceuticals
11.5. CSL312: CSL Behring
12. Hereditary Angioedema: 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of Hereditary Angioedema in 7MM
13. Seven Major Market Outlook
13.1. United States Market Size
13.2. Germany
13.3. France
13.4. Italy
13.5. Spain
13.6. United Kingdom
13.7. Japan
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Market Access and Reimbursement
18. Case studies
18.1. Hereditary angioedema (HAE): a cause for recurrent abdominal pain
18.2. Hereditary Angioedema Type II: First Presentation in Adulthood with Recurrent Severe Abdominal Pain
18.3. Hereditary angioedema type I in a female patient: a case report
19. KOL Views
20. Bibliography
21. Appendix
21.1. Report Methodology
22. Publisher Capabilities
23. Disclaimer
24. About the Publisher
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/t4g3nc
